Docoh
Loading...

HALO Halozyme Therapeutics

APP
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
16 Sep 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 21 May 21
APP
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
9 Sep 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 21 May 21
GRANT
Utility
PH20 polypeptide variants, formulations and uses thereof
20 Jul 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 25 Jun 20
GRANT
Utility
PH20 polypeptide variants, formulations and uses thereof
22 Jun 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 19 Mar 20
APP
Utility
SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
28 Jan 21
Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies.
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 2 Oct 20
GRANT
Utility
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
26 Jan 21
Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies.
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 2 Apr 19
GRANT
Utility
PH20 polypeptide variants, formulations and uses thereof
14 Dec 20
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 1 Aug 16
APP
Utility
Modified Hyaluronidases and Uses In Treating Hyaluronan-associated Diseases and Conditions
25 Nov 20
Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders.
Gregory I. Frost, Ping Jiang, Curtis B. Thompson
Filed: 15 Jul 20
APP
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
7 Oct 20
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
GE WEI, H. MICHAEL SHEPARD, QIPING ZHAO, ROBERT JAMES CONNOR
Filed: 24 Jun 20
APP
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
12 Aug 20
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 18 Mar 20
GRANT
Utility
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
16 Mar 20
The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies.
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 22 Feb 18
APP
Utility
Methods of Selecting Subjects for Combination Cancer Therapy with a Polymer-conjugated Soluble PH20
20 Nov 19
Provided herein are methods of selecting subjects having cancer for combination therapy that includes administering an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme.
Song Wang, Darin M. Taverna, Carl Di Casoli, Nicholas Willumsen, Morten Karsdal, Thomas Mueller
Filed: 14 May 19
APP
Utility
Modified Hyaluronidases and Uses In Treating Hyaluronan-associated Diseases and Conditions
6 Nov 19
Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders.
Gregory I. Frost, Ping Jiang, Curtis B. Thompson
Filed: 20 May 19
  • 1
Patents are sorted by USPTO publication date, most recent first